SCHEMBL8259256

SCHEMBL8259256

Cn1cc(CCCO)c2cc(Cl)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.46
CDK2 P24941 1/20 0.46
SNCA P37840 1/20 0.45
KMT2A Q03164 3/20 0.44
HTR1D P28221 1/20 0.43
KCNH2 Q12809 1/20 0.43
RXFP1 Q9HBX9 2/20 0.43
POLB P06746 2/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
RAB9A P51151 1/20 0.42
GPR55 Q9Y2T6 1/20 0.42
HTR6 P50406 1/20 0.42
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NQO2 P16083 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6242735 0.91 CDK2 (0.47) ADRB2CDK2SNCAKMT2AHTR1D
SCHEMBL14155127 0.86 KCNH2 (0.50) ADRB2CDK2SNCAKMT2AHTR1D
SCHEMBL8259649 0.85 ADRB2 (0.46) ADRB2CDK2SNCAKMT2AHTR1D
SCHEMBL18885193 0.84 KMT2A (0.45) ADRB2CDK2SNCAKMT2AHTR1D
SCHEMBL14664390 0.83 KCNH2 (0.59) ADRB2CDK2SNCAKMT2AHTR1D
SCHEMBL7734844 0.82 KDM4E (0.51) ADRB2SNCAKMT2AHTR1DRXFP1
SCHEMBL379053 0.81 ADRB2 (0.64) ADRB2CDK2SNCAKMT2AHTR1D
Hydrochloric Acid SCHEMBL7681619 0.80 ADRB2 (0.62) ADRB2CDK2SNCAKMT2AHTR1D
SCHEMBL18509434 0.79 KMT2A (0.54) CDK2SNCAKMT2ARXFP1MEN1
SCHEMBL8304470 0.79 ADRB2 (0.70) ADRB2KMT2AMEN1RAB9AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142397-A2 PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARMECEUTICALS B.V. (NL) 2007-06-21 US disclosed
WO-2006061379-A1 PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARMACEUTICALS B.V. (NL) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142397-A2 PHENYPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION HTR2C, HTR2A, HTR5A ADRB2 20/4885CDK2 1188/4885SNCA 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.